Results 51 to 60 of about 6,793 (233)

The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung [PDF]

open access: yes, 2018
Introduction: Because small-cell lung carcinomas (SCLC) are seldom resected, human materials for study are limited. Thus, genetically engineered mouse models (GEMMs) for SCLC and other high-grade lung neuroendocrine (NE) carcinomas are crucial for ...
Berns, Anton   +11 more
core   +1 more source

Classification of subtypes including LCNEC in lung cancer biopsy slides using convolutional neural network from scratch [PDF]

open access: yesScientific Reports, 2022
AbstractIdentifying the lung carcinoma subtype in small biopsy specimens is an important part of determining a suitable treatment plan but is often challenging without the help of special and/or immunohistochemical stains. Pathology image analysis that tackles this issue would be helpful for diagnoses and subtyping of lung carcinoma.
Jung Wook Yang   +3 more
openaire   +3 more sources

Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer

open access: yesBMC Cancer, 2023
Background Pulmonary large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC) are two types of high-grade neuroendocrine carcinomas of the lung with poor prognosis.
Liling Huang   +5 more
doaj   +1 more source

Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas [PDF]

open access: yes, 2015
Background: There is controversy whether patients diagnosed with large-cell neuroendocrine carcinoma (LCNEC) should be treated according to protocols for non-small cell lung cancers (NSCLC) or small cell lung cancers (SCLC), especially with regard to the
Debus, Jürgen   +12 more
core   +1 more source

Pulmonary large cell neuroendocrine carcinoma with adrenal oligorecurrence successfully treated by adrenalectomy

open access: yesRespirology Case Reports, 2020
A 63‐year‐old man suspected of having lung cancer underwent right upper lobectomy and was diagnosed with large cell neuroendocrine carcinoma (LCNEC). Eleven months after surgery, he developed an oligorecurrence in the adrenal gland and underwent left ...
Hiroki Sato   +5 more
doaj   +1 more source

Endotracheal Metastasis Causing Airway Obstruction [PDF]

open access: yes, 2020
Endotracheal metastasis, a critical complication of primary lung cancer, is an extremely rare lesion. A 73-year-old woman who had previously received treatment for lung cancer presented to our emergency department with dyspnea.
Fujiwara, Takashi   +2 more
core  

Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature [PDF]

open access: yes, 2013
PURPOSE: A high rate of response to treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been observed in certain patients (women, of East Asian ethnicity, with non-smoking history and adenocarcinoma histology) with ...
Daisuke Kasai   +6 more
core   +1 more source

Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors [PDF]

open access: yes, 2016
Background: Lung cancer is the leading cause of cancer-related deaths worldwide. 25% show neuroendocrine differentiation (typical/atypical carcinoids, large-/small-cell neuroendocrine carcinomas).
Christoph, Daniel   +5 more
core   +1 more source

New models of large-cell neuroendocrine carcinoma and small-cell lung carcinoma

open access: yesMolecular & Cellular Oncology, 2020
High-grade neuroendocrine lung carcinomas (LCNEC, SCLC) are recalcitrant cancers for which no optimal management has been achieved. We have recently described two models of LCNEC and SCLC developed upon inactivation of 4 tumor suppressors genes (Rb1 (RB ...
Mirentxu Santos
doaj   +1 more source

MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma

open access: yesWorld Journal of Surgical Oncology, 2018
Background The response to temozolomide (TMZ) treatment in small-cell lung cancer (SCLC) correlated with O(6)-methylguanine -DNA methyltransferase (MGMT) promoter methylation. 1p/19q co-deletion within oligodendroglioma is a responsive predictor for TMZ.
Lei Lei   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy